AJOVista LLC Invests $42,000 in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

AJOVista LLC bought a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,794 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

A number of other large investors have also bought and sold shares of CBAY. RA Capital Management L.P. bought a new position in CymaBay Therapeutics in the third quarter worth approximately $103,475,000. Vanguard Group Inc. raised its holdings in CymaBay Therapeutics by 11.6% during the third quarter. Vanguard Group Inc. now owns 5,747,587 shares of the biopharmaceutical company’s stock worth $85,697,000 after buying an additional 598,707 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of CymaBay Therapeutics by 12.3% during the fourth quarter. Jennison Associates LLC now owns 3,992,711 shares of the biopharmaceutical company’s stock valued at $94,308,000 after buying an additional 437,437 shares during the last quarter. Fred Alger Management LLC bought a new stake in shares of CymaBay Therapeutics during the third quarter worth about $32,389,000. Finally, FMR LLC raised its holdings in shares of CymaBay Therapeutics by 13,559.7% in the 3rd quarter. FMR LLC now owns 1,568,948 shares of the biopharmaceutical company’s stock worth $23,393,000 after acquiring an additional 1,557,462 shares during the last quarter. 95.03% of the stock is currently owned by institutional investors and hedge funds.

CymaBay Therapeutics Stock Performance

Shares of CymaBay Therapeutics stock opened at $32.48 on Monday. The stock has a market capitalization of $3.73 billion, a P/E ratio of -33.48 and a beta of 0.32. CymaBay Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $32.50. The stock’s 50-day simple moving average is $32.43 and its 200 day simple moving average is $25.62.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.42 million. Equities research analysts forecast that CymaBay Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Janet Dorling sold 6,000 shares of CymaBay Therapeutics stock in a transaction on Monday, February 12th. The stock was sold at an average price of $31.97, for a total value of $191,820.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

CBAY has been the subject of a number of analyst reports. Jonestrading reissued a “hold” rating on shares of CymaBay Therapeutics in a research report on Tuesday, February 13th. BTIG Research restated a “neutral” rating on shares of CymaBay Therapeutics in a report on Tuesday, February 13th. Cantor Fitzgerald downgraded CymaBay Therapeutics from an “overweight” rating to a “neutral” rating and set a $32.50 price target for the company. in a research report on Tuesday, February 13th. SVB Leerink reaffirmed a “market perform” rating and set a $32.50 target price on shares of CymaBay Therapeutics in a research report on Tuesday, February 20th. Finally, HC Wainwright restated a “neutral” rating and set a $32.50 price target on shares of CymaBay Therapeutics in a research report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, CymaBay Therapeutics has an average rating of “Hold” and an average target price of $28.65.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).